<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>28(5)</volume><submitter>Lakkunarajah S</submitter><pubmed_abstract>There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOL</pubmed_abstract><journal>Current oncology (Toronto, Ont.)</journal><pagination>4031-4041</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8535138</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis.</pubmed_title><pmcid>PMC8535138</pmcid><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Yamanaka E</pubmed_authors><pubmed_authors>Lakkunarajah S</pubmed_authors><pubmed_authors>Warner A</pubmed_authors><pubmed_authors>Breadner DA</pubmed_authors><pubmed_authors>Welch S</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis.</name><description>There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were retrospectively analyzed. Patients who received at least 6 weeks of adjuvant therapy were included. The primary objective was to assess the influence of dose index (DI) and relative dose intensity (RDI) on DFS and OS at 3 and 5 years in patients receiving fluorouracil-based doublet therapy with oxaliplatin (FOLFOX) (5-FU and oxaliplatin assessed separately), or capecitabine monotherapy. In the capecitabine group, DFS rates for 3 and 5 years were 66.7% and 57.6%, respectively, while OS rates were 80.3% and 66.7%, respectively. Those who received FOL</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-05-29T20:29:00.642Z</modification><creation>2025-05-29T20:29:00.642Z</creation></dates><accession>S-EPMC8535138</accession><cross_references><pubmed>34677260</pubmed><doi>10.3390/curroncol28050342</doi></cross_references></HashMap>